Diagnosis of Renal Cell Carcinoma on 68Ga-PSMA PET-CT and Radioligand Therapy With 177Lu-EB-PSMA-617
Latest Information Update: 07 Dec 2023
At a glance
- Drugs Gallium (68Ga) gozetotide (Primary) ; Lutetium (177Lu) vipivotide tetraxetan (Primary)
- Indications Renal cell carcinoma
- Focus Diagnostic use
Most Recent Events
- 30 Jun 2022 Status changed from suspended to recruiting, according to a Novartis media release.
- 30 Jun 2022 According to Novartis media release, company has remediated the issues that led to the temporary, voluntary suspension. These issues did not affect patient safety, and no risk to patients from the doses previously produced at these sites was identified.Company restarted screening and enrollment for clinical trials with 177Lu-PSMA-617 (lutetium Lu 177 vipivotide tetraxetan) in the US, in most countries globally.
- 05 May 2022 According to Novartis media release, Novartis is putting a temporary hold on screening and enrollment for 177Lu-PSMA-617 clinical trials globally, hence status changed to suspended.